🗞️ Why in News The Indian Council of Agricultural Research announced on August 4, 2026 the technical details of India’s first indigenous vaccine against African Swine Fever, developed at the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal. The vaccine had earlier been dedicated to the nation at the 98th ICAR Foundation Day on July 16, 2026.
What African Swine Fever Is
African Swine Fever (ASF) is a viral haemorrhagic disease of domestic and wild pigs. Three facts define its policy significance:
- There is no cure. Treatment is not an option; only prevention and containment are.
- Mortality approaches 100 per cent in infected pigs.
- It is not zoonotic. ASF does not infect humans. This is a standard examination trap, and it also matters practically, because public panic about a non-zoonotic animal disease drives market collapse faster than the disease itself.
ASF must be distinguished from Classical Swine Fever (CSF), an entirely different virus of a different family, for which India already had an indigenous vaccine. Conflating the two is the second common error.
ASF is a notifiable disease under the World Organisation for Animal Health (WOAH), meaning member countries are obliged to report outbreaks. It first entered India in 2020, through the North-Eastern states.
Why a Vaccine Was So Hard
ASF virus is large, complex and has resisted vaccine development for decades. Conventional inactivated vaccines do not confer protection. The workable approach has been live attenuated virus, meaning a weakened strain that provokes immunity without causing disease.
Producing a live attenuated ASF vaccine requires growing the virus in cell culture. ASF virus replicates naturally in primary porcine macrophages, which must be freshly harvested from pigs. Primary macrophage culture cannot be scaled, standardised or stored like a cell line, so a candidate vaccine must first be adapted to grow in one, and those that succeeded did so on proprietary or restricted platforms.
This is the constraint that international candidates have had to solve with patented proprietary cell lines. Vietnam licensed the first commercial ASF vaccines on that basis, and freedom from such a proprietary platform is ICAR’s own stated point of differentiation.
The Indian Contribution
Scientists at ICAR-NIHSAD created a novel attenuated ASF Virus Genotype II strain, carrying specific gene deletions, derived from an Indian field isolate. They then adapted it to grow in the MA-104 cell line.
MA-104 is commercially available. It is a widely used continuous cell line, already employed in veterinary vaccine production, that can be purchased, banked, characterised and scaled under standard manufacturing conditions.
That is the breakthrough, and it is worth stating precisely in an answer: the scientific novelty is the attenuated Indian-isolate strain, but the manufacturability comes from the cell line. A vaccine that cannot be produced at scale and low cost does not control a disease in a country with millions of smallholder pigs.
Two further design points follow from using an Indian field isolate. The strain matches the genotype actually circulating in India, and India is not dependent on a foreign licensor for the seed virus.
Market availability is expected roughly six months out, after auction of the technology, patenting and commercial manufacture by a pharmaceutical partner.
Why This Changes the Control Strategy
This is the analytical core of the topic.
Without a vaccine, the only control tool for ASF is culling: destroying infected herds and those within a containment radius, with compensation.
Culling has a structural flaw. It destroys the livelihood of the farmer who reports the outbreak. In the North-East, where pig rearing is simultaneously a household asset, a cultural practice and an informal trade network, the rational response of a smallholder facing culling is to conceal the outbreak and sell the animals quickly. Concealment spreads the disease faster than the disease spreads on its own.
The control strategy therefore fails not because the science is wrong but because the incentives are inverted: the state asks the farmer to bear a total loss in exchange for a public good.
A cheap, scalable vaccine inverts the inversion. Immunisation protects the farmer’s asset instead of destroying it, so the farmer’s incentive and the state’s objective align. Compliance stops depending on enforcement.
The Counter-Argument
A good answer must engage the risks, because live attenuated ASF vaccines carry two documented ones.
Reversion to virulence. An attenuated strain can, in principle, regain virulence in the field. Gene-deletion attenuation is more stable than passage attenuation, but the risk is not zero and requires post-marketing surveillance.
DIVA capability. DIVA means Differentiating Infected from Vaccinated Animals. If a serological test cannot distinguish an animal that was vaccinated from one that was infected, a country loses the ability to demonstrate freedom from disease, which is what trading partners require before accepting exports. Mass deployment without DIVA capability could compromise India’s ability to certify disease freedom.
Balanced verdict. These are arguments for a controlled, surveilled rollout with a companion diagnostic, not against the vaccine. The alternative on offer is a control strategy that has demonstrably failed since 2020 because it asks farmers to destroy their own assets.
UPSC Relevance
GS Paper 3: Science and technology developments and their applications; biotechnology; animal husbandry; food security and allied sectors; issues relating to intellectual property rights.
GS Paper 2: Government policies and interventions in the health and agriculture sectors; issues arising from their design and implementation.
GS Paper 1 and 2 spillover: Livelihoods and society in North-East India.
Prelims focus: ICAR-NIHSAD Bhopal; MA-104 cell line; ASFV Genotype II; ASF is not zoonotic; ASF versus Classical Swine Fever; WOAH notifiable disease; ASF entered India in 2020; 98th ICAR Foundation Day, July 16, 2026.
Mains angle: “A control strategy that asks a farmer to destroy his own asset will be evaded, not enforced.” Examine how the availability of a scalable ASF vaccine changes the incentive structure of animal disease control in India, and discuss the surveillance requirements for safe deployment of a live attenuated vaccine.
📌 Facts Corner, Knowledgepedia
African Swine Fever Vaccine:
- Developed at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal
- Technical announcement: August 4, 2026; dedicated to the nation at the 98th ICAR Foundation Day, July 16, 2026, New Delhi
- Platform: MA-104 cell line, commercially available, which enables large-scale low-cost manufacture
- Strain: novel attenuated ASFV Genotype II with specific gene deletions, from an Indian field isolate
- Market availability expected roughly six months out, after technology auction, patenting and commercial manufacture
African Swine Fever:
- No cure; mortality approaches 100 per cent in infected pigs
- Not zoonotic: does not infect humans
- Distinct from Classical Swine Fever (CSF), a different virus of a different family
- Notifiable under the World Organisation for Animal Health (WOAH), formerly the OIE
- First entered India in 2020, through the North-Eastern states
- Natural host cell: primary porcine macrophages, which cannot be scaled or standardised
Key Concepts:
- Live attenuated vaccine: a weakened live organism that provokes immunity without disease
- DIVA: Differentiating Infected from Vaccinated Animals, needed to certify disease freedom for trade
- Reversion to virulence: the risk that an attenuated strain regains disease-causing capacity
Institutional Framework:
- ICAR: Indian Council of Agricultural Research, under the Department of Agricultural Research and Education (DARE), Ministry of Agriculture and Farmers’ Welfare, established 1929 as the Imperial Council of Agricultural Research
- ICAR-NIHSAD, Bhopal, is India’s high-containment animal disease laboratory, formerly the High Security Animal Disease Laboratory. It operates at ABSL-3+, with an upgrade towards ABSL-4 announced in 2025 and not yet operational; India’s only functional civilian BSL-4 facility is the National Institute of Virology, Pune
- Related programmes: National Animal Disease Control Programme (NADCP) for foot-and-mouth disease and brucellosis; Livestock Health and Disease Control Programme (LHDCP)
- Animal husbandry is a State subject under Entry 15 of the State List, which is why disease control depends on state veterinary departments
Sources: ICAR, PIB, Department of Animal Husbandry and Dairying
Source: The Cell Line Is the Breakthrough: India's Indigenous African Swine Fever Vaccine — Ujiyari.com | Free UPSC & State PCS Current Affairs
